Yellox (bromfenac) eye drops launched

Yellox (bromfenac) eye drops are now available for the treatment of ocular inflammation following cataract extraction.

Yellox is administered less often than many other anti-inflammatories, which may aid patient adherence
Yellox is administered less often than many other anti-inflammatories, which may aid patient adherence

Bromfenac is an NSAID that exerts its anti-inflammatory effect through inhibition primarily of cyclooxygenase-2, and to a lesser extent cyclooxygenase-1.1

Efficacy was displayed in 2 phase III, randomised, placebo-controlled, double-blind studies (n=527).1 In patients who received bromfenac twice daily starting approximately 24 hours after surgery and continuing for up to 14 days, a greater proportion experienced complete clearance of ocular inflammation on day 15 compared with patients who received placebo (64.0% vs 43.3%; p<0.0001). In addition, anterior chamber cell and flare scores within 2 weeks of surgery were lower in the treatment arms than in the placebo groups (flare score ≤1, 85.1% vs 52.0%).

REFERENCES

  1. Yellox Summary of Product Characteristics, May 2011.

View Yellox drug record

Further Information: Bausch & Lomb

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more